首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >A site-specifically conjugated anti-CD22 antibody bearing an MDR1-resistant maytansine payload yields excellent efficacy and safety in preclinical models

【24h】

A site-specifically conjugated anti-CD22 antibody bearing an MDR1-resistant maytansine payload yields excellent efficacy and safety in preclinical models

机译：带有MDR1抗性美登素有效负载的位点特异性缀合的抗CD22抗体在临床前模型中具有出色的疗效和安全性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2016年第null期|共2页
作者
Rabuka D.; Drake P.; Carlson A.; McFarland J.; Barfield R.; Banos S.; Zmolek W.; Kim Y.; Huang B.; Garofalo A.; Kudirka R.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
专利

1. CAT-02-106, a Site-Specifically Conjugated Anti-CD22 Antibody Bearing an MDR1-Resistant Maytansine Payload Yields Excellent Efficacy and Safety in Preclinical Models [J] . Drake Penelope M., Carlson Adam, McFarland Jesse M., Molecular cancer therapeutics . 2018,第1期

机译：CAT-02-106，轴承MDR1抗性Maytansine有效载荷的位点特异性缀合的抗CD22抗体在临床前模型中产生了出色的功效和安全性
2. A site-specifically conjugated anti-CD22 antibody bearing an MDR1-resistant maytansine payload yields excellent efficacy and safety in preclinical models [J] . Rabuka D., Drake P., Carlson A., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2016,第Null期

机译：带有MDR1抗性美登素有效负载的位点特异性缀合的抗CD22抗体在临床前模型中具有出色的疗效和安全性
3. A site-specifically conjugated anti-CD22 antibody bearing an MDR1-resistant maytansine payload yields excellent efficacy and safety in preclinical models [J] . Rabuka D., Drake P., Carlson A., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2016,第Null期

机译：轴承MDR1抗性Maytansine有效载荷的位点特异性缀合的抗CD22抗体在临床前模型中产生了出色的功效和安全性
4. CAT-02-106, a Site-Specifically Conjugated Anti-CD22 Antibody Bearing an MDRl-Resistant Maytansine Payload, Yields Excellent Efficacy and Safety in Preclinical Models [C] . Robyn Μ. Barfield, Penelope Μ. Drake, Adam Carlson, Protein Engineering Summit. . 2018

机译：CAT-02-106，一种耐受MDRL抗性Maytansine有效载荷的位点特异性缀合的抗CD22抗体，在临床前模型产生优异的功效和安全性
5. Improving Antibody-Drug Conjugate Tumor Distribution and Efficacy Using Single-Cell Imaging and Multiscale Modeling [D] . Cilliers, Cornelius 2018

机译：使用单细胞成像和多尺度建模改善抗体药物结合的肿瘤分布和功效
6. IL3RA-Targeting Antibody–Drug Conjugate BAY-943 with a Kinesin Spindle Protein Inhibitor Payload Shows Efficacy in Preclinical Models of Hematologic Malignancies [O] . Dennis Kirchhoff, Beatrix Stelte-Ludwig, Hans-Georg Lerchen, 2020

机译：IL3ARA靶向抗体 - 药物共轭湾-943具有Kinesin主轴蛋白抑制剂有效载荷显示血液学恶性肿瘤临床前模型的疗效
7. Efficacy of an anti-CD22 antibody-monomethyl auristatin E conjugate in a preclinical xenograft model of precursor B-cell acute lymphoblastic leukemia [O] . Sakiko Yoshida, Emily Tuscano, Connie Duong, 2016

机译：抗CD22抗体 - 单甲基Auristatin E缀合物在前体B细胞急性淋巴细胞白血病临床前异种移植模型中缀合物的疗效

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号